

Abstract Submitted
for the MAR11 Meeting of
The American Physical Society

Attachment of a Genetically Engineered Antibody to a Carbon Nanotube Transistor for Detection of Prostate Cancer Biomarkers

MITCHELL LERNER, JENNIFER DAILEY, BRETT GOLDSMITH, University of Pennsylvania Department of Physics and Astronomy, MATTHEW ROBINSON, Fox Chase Cancer Center, A.T. CHARLIE JOHNSON, University of Pennsylvania Department of Physics and Astronomy — We have developed a novel detection method for osteopontin (OPN) by attaching an engineered single chain variable fragment (scFv) protein with high binding affinity for OPN to a carbon nanotube transistor. Osteopontin is a potential new biomarker for prostate cancer; its presence in humans is already associated with several forms of cancer, arthritis, osteoporosis and stress. Prostate cancer is the most commonly diagnosed cancer and second leading cause of cancer deaths among American men and as such represents a major public health issue. Detection of early-stage cancer often results in successful treatment, with long term disease-free survival in 60-90% of patients. Electronic transport measurements are used to detect the presence of OPN in solution at clinically relevant concentrations.

Mitchell Lerner
University of Pennsylvania Department of Physics and Astronomy

Date submitted: 19 Nov 2010

Electronic form version 1.4